Propulsion of Sarcopenia Clinical Trial Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Domain | DelveInsight
(Albany, United States) As per DelveInsight’s assessment, globally, the Sarcopenia Pipeline constitutes 8+ key companies continuously working towards developing 10+ Sarcopenia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Sarcopenia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Sarcopenia NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Sarcopenia Pipeline treatment landscape of the report, click here @ Sarcopenia Pipeline Outlook
Key Takeaways from the Sarcopenia Pipeline Report
- DelveInsight’s Sarcopenia Pipeline analysis depicts a robust space with 8+ active players working to develop 10+ pipeline treatment therapies.
- The leading companies working in the Sarcopenia market include Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others.
- Promising Sarcopenia Pipeline Therapies in the various stages of development include REGN1033 (SAR391786), Bimagrumab, Comparator: MK-0773, Astaxanthin formulation, Exercise Training, LPCN 1148, and others.
- On March 2023, MyMD Pharmaceuticals Inc. announced a study of phase 2 clinical trials for MYMD-1 600MG. The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines.
- On July 2023, Australian Catholic University announced a study of phase 4 clinical trials for Pendulum WBF-038. To evaluate the effect of 12 months of supplementation with a probiotic (probiotic plus prebiotic; 2 capsules per day) on relative change (%) in total volumetric bone density (measured using high resolution peripheral quantitative computed tomography [HR-pQCT]) of the distal tibia.
Sarcopenia Overview
Sarcopenia is a musculoskeletal disease in which muscle mass, strength, and performance are significantly compromised with age. Sarcopenia most commonly affects elderly and sedentary populations and patients who have comorbidities that affect the musculoskeletal system or impair physical activity.
For further information, refer to the detailed Sarcopenia Unmet Needs, click here for Sarcopenia Ongoing Clinical Trial Analysis
Sarcopenia Emerging Drugs Profile
- Sarconeos (BIO101): Biophytis
- MYMD-1: MyMD Pharmaceuticals
Sarcopenia Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the therapies for Sarcopenia. The Sarcopenia companies which have their Sarcopenia drug candidates in the most advanced stage, i.e. phase III include, Biophytis.
Request a sample and discover the recent advances in Sarcopenia Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Sarcopenia Segmentation
Sarcopenia Drugs and Companies
- REGN1033 (SAR391786): Regeneron Pharmaceuticals
- Bimagrumab: Novartis Pharmaceuticals
- Comparator: MK-0773: Merck Sharp & Dohme LLC
Sarcopenia Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Sarcopenia Therapeutics Market include-
Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others.
Dive deep into rich insights for drugs for the Sarcopenia Pipeline, Click here @ Sarcopenia Unmet Needs and Analyst Views
Scope of the Sarcopenia Pipeline Report
- Coverage- Global
- Companies- Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others.
- Therapies- REGN1033 (SAR391786), Bimagrumab, Comparator: MK-0773, Astaxanthin formulation, Exercise Training, LPCN 1148, and others.
- Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Sarcopenia Merger and acquisitions, Licensing Activities
Table of Content
- Introduction
- Executive Summary
- Sarcopenia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Sarcopenia – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Sarconeos (BIO101): Biophytis
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- MYMD-1: MyMD Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- PF-1801: PhaseBio Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Sarcopenia Key Companies
- Sarcopenia Key Products
- Sarcopenia- Unmet Needs
- Sarcopenia- Market Drivers and Barriers
- Sarcopenia- Future Perspectives and Conclusion
- Sarcopenia Analyst Views
- Sarcopenia Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
